Serum Tumor Markers
Conditions
Brief summary
Patients with liver cancer expected to undergo radiofrequency ablation or transvascular embolization. Relevant tumor markers (AFP and methylation analysis) were performed. The two data are then counted and compared.
Detailed description
The subjects of this study were patients who were diagnosed with liver cancer by physicians based on AASLD clinical criteria or pathological biopsy. Patients are those who received radiofrequency ablation or transvascular embolization in National Taiwan University Hospital. Which excludes weakness and inability to cooperate Patients with blood test, under the condition of fully informed consent, complete blood test related tumor indicators (AFP and methylation analysis). The two data are then counted Compare.
Interventions
DIAGNOSTIC_TESTMet-score
methylation analysis
Sponsors
National Taiwan University Hospital
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 85 Years
Inclusion criteria
1. Patients diagnosed with liver cancer by AASLD clinical criteria or pathological sections are planned to receive treatment at National Taiwan University Hospital Liver local treatment such as radiofrequency ablation or transvascular embolization. 2. Be over 20 years old. 3. Under the condition of informed consent, willing to sign the consent form of the subjects.
Exclusion criteria
1. Patients who are weak and unable to cooperate with blood test. 2. Kidney dysfunction, serum creatinine greater than 1.5mg/dl, it is judged that computer tomography or MRI cannot be performed Vibrate the injector.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate efficacy (methylation profiling results) | 3 month after treatment | Correlation of methylation profiling results with AFP and tumor treatment response. |
Countries
Taiwan
Outcome results
None listed